Mkts

Denali Therapeutics Inc.

NASDAQ: DNLI
$19.39-0.34 (-1.72%)
As of Nov 12, 9:30 AM ET

Key statistics

Day range
18.8019.59
52-week range
15.3427.30
Today
Open19.38
Previous close19.39
Volume29.0K
Valuation
Market cap2.91B
P/E ratio—
EPS (TTM)-2.84
Income & risk
Dividend / yield—
Beta1.07
Avg volume1.70M
Discussion

DNLI News

Stories mentioning DNLI from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue0.000.000.00
Cost of Goods Sold
Gross Profit0.000.000.000.00
Operating Expenses
Research & Development103,84697,905101,950102,696116,22799,78798,23891,399
Sales General & Admin
Total Operating Expenses137,357137,365137,434134,963145,580129,846123,187116,593
Operating Income (Loss)(137,357)(137,365)(137,434)(134,963)(145,580)(129,846)(123,187)(116,593)
Interest Income
Interest Expense
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(128,447)(128,549)(126,902)(124,119)(132,970)(114,753)(107,192)(99,026)
Earnings Per Share (Basic)(0.69)(0.74)(0.74)(0.72)(0.78)(0.70)(0.63)(0.59)
Earnings Per Share (Diluted)(0.69)(0.74)(0.74)(0.72)(0.78)(0.70)(0.63)(0.59)
Weighted Average Shares Outstanding (Basic)186,637172,649172,421171,450171,222164,474169,457168,831
Weighted Average Shares Outstanding (Diluted)186,637172,649172,421171,450171,222164,474169,457168,831

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About DNLI

Denali Therapeutics Inc. (NASDAQ: DNLI) is a stock listed on the Nasdaq Stock Market under the ticker symbol DNLI. It last traded at $19.39 (Nov 12, 2026, 9:30 AM ET), down 1.7% on the day. That gives Denali Therapeutics a market capitalisation of $2.9B.

Over the past 52 weeks DNLI has traded between $15.34 and $27.30.

For the quarter ended Mar 31, 2026 it reported a net loss of $128.4M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$128.4M
Dec 31, 2025—-$128.5M
Sep 30, 2025—-$126.9M
Jun 30, 2025—-$124.1M

From Denali Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…